$2.30+0.00 (+0.22%)
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
Aytu BioPharma, Inc. in the Healthcare sector is trading at $2.30. Wall Street consensus targets $9.33 (3 analysts), implying a +305.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $3.07, remaining 3.4% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), inc...
Moby summary of Aytu BioPharma, Inc.'s Q3 2026 earnings call
Aytu BioPharma Inc (AYTU) reports robust initial traction for Exua despite a decline in net revenue and profit margins.
Need a quote from a Motley Fool analyst? As the operator indicated, during today's call, we will be discussing Aytu BioPharma's fiscal 26 third quarter operational and financial results. Joining us on today's call is Aytu's chief executive officer, Joshua R. Disbrow and Ryan J. Selhorn, the company's chief financial officer.
Aytu BioPharma (NASDAQ:AYTU) released third-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data and transcripts, visit https://www.benzinga.com/apis/. The full earnings call is available at https://www.webcaster5.com/Webcast/Page/2142/53861 Summary Aytu Biopharma Inc reported a net revenue of $12.4 million for Q3 2026, down 33% year over year, impacted by a strategic shi
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?